Mass Balance Study of [14C] TAS-205 in Healthy Volunteers

Phase 1 Completed 6 enrolled Taiho Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the pharmacokinetics, mass balance recovery, metabolite profile and metabolite identification of \[14C\]TAS-205 following oral single doses.

Timeline

Start: 2021-03-22
Primary completion: 2021-06-15
Completion: 2022-05-27

Publications

Hanada R, Takenaka T. Phase 1 Mass Balance Study of Pizuglanstat: An Investigational Hematopoietic Prostaglandin D Synthase Inhibitor. Clin Pharmacol Drug Dev. 2025 Mar;14(3):200-208. doi: 10.1002/cpdd.1504. Epub 2025 Jan 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pizuglanstat	Unknown	400 mg	Oral

Indications

No indication recorded.